
Leigh Goedeke, PhD
About Me
Dr. Leigh Goedeke received her BS in Biology from Gettysburg College in 2009 and PhD in Biomedical Sciences from NYU School of Medicine in 2015. After completing her postdoctoral training at Yale School of Medicine, Dr. Goedeke was recruited to the Cardiovascular Research Institute at the Icahn School of Medicine at Mount Sinai in the Spring of 2022, where she is currently an Assistant Professor of Medicine (Cardiology and Endocrinology). Dr. Goedeke’s research focuses on understanding how altered mitochondrial function–and more broadly metabolism– contributes to type 2 diabetes and residual cardiovascular disease risk. Using a combination of in vivo physiology, molecular biology, stable isotope tracer methodology and integrative multi-omics, her laboratory explores the critical metabolic pathways that underlie atherosclerotic plaque progression and vulnerability. Specifically, the lab is focused on two integrated areas of research: i) identification of novel metabolic hubs that regulate traditional atherosclerotic risk factors and ii) mitochondrial energy metabolism and vessel wall heterogeneity in diabetic atherosclerosis.
Language
English
Position
ASSISTANT PROFESSOR | Medicine, Cardiology, ASSISTANT PROFESSOR | Medicine, Endocrinology, Diabetes and Bone Disease
Research Topics
Atherosclerosis, Cardiovascular, Diabetes, Endocrinology, Endothelial Cells, Genetics, Immunology, Insulin, Lipid Signaling, Liver, Macrophage, Metabolism, Mitochondria, Obesity, Oxidative Stress, Translational Research
Multi-Disciplinary Training Areas
Disease Mechanisms and Therapeutics (DMT)
Education
BS, Gettysburg College
PhD, NYU School of Medicine
PhD, Yale School of Medicine
Awards
2022
Schneider-Lesser Foundation Award for Junior Faculty
2019
Pathway to Independence Award (K99/R00)
NIH (NHLBI)
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Below are financial relationships with industry reported by Dr. Goedeke during 2025 and/or 2026. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting or Other Professional Services
Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership- OrsoBio
- Bain Capital Life Sciences
Equity
(Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)- OrsoBio
Mount Sinai’s faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.